Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMANTADINE vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amantadine is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of viral uncoating, thereby blocking influenza A M2 ion channel. In Parkinson's disease, it is thought to increase dopamine release and inhibit its reuptake, and may also have anticholinergic and NMDA receptor antagonist effects.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Influenza A virus infection (prophylaxis and treatment),Parkinson's disease (symptomatic treatment),Drug-induced extrapyramidal reactions
Mild to moderate pain,Fever
100 mg orally twice daily for Parkinson's disease; 100 mg orally twice daily for influenza A prophylaxis/treatment (up to 200 mg/day).
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life: 10-14 hours in young adults, up to 24 hours in elderly; prolonged to >24 hours in renal impairment
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Amantadine is primarily excreted unchanged in urine via glomerular filtration and tubular secretion. It undergoes minimal hepatic metabolism (less than 10%) with no major identified metabolites.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal: 90% as unchanged drug via glomerular filtration and tubular secretion; fecal: <10%
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
60-70% bound, primarily to albumin
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Vd: 4-10 L/kg; indicates extensive tissue binding and penetration into brain (CSF: 50-80% of plasma concentration)
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral: 86-90%; IV: 100%
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Cr Cl 30-50 m L/min: 100 mg once daily; Cr Cl 15-29 m L/min: 100 mg every other day; Cr Cl <15 m L/min or hemodialysis: 200 mg every 7 days.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
No specific Child-Pugh adjustments; use caution in severe hepatic impairment due to potential toxicity.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Influenza A prophylaxis/treatment: 1-9 years: 5 mg/kg/day (max 150 mg/day) in 2 divided doses; 10-12 years: 100 mg twice daily; 13-16 years: 100 mg twice daily. Parkinson's: not recommended.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Use lower starting dose (100 mg daily) due to age-related renal decline; frequent monitoring for neuropsychiatric effects.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
None.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Can cause CNS effects such as confusion, hallucinations, and seizures, especially in elderly or those with renal impairment,May exacerbate psychiatric disorders,Abrupt discontinuation may precipitate parkinsonian crisis or neuroleptic malignant syndrome in patients with Parkinson's disease,Avoid in patients with uncontrolled epilepsy,Renal dose adjustment required
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to amantadine or any component,Severe uncontrolled epilepsy,Concomitant use with live attenuated influenza vaccine (since antiviral activity may impair vaccine efficacy)
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
No specific food interactions. Avoid alcohol and limit caffeine intake due to potential increased CNS effects. Take with food if gastrointestinal upset occurs.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
FDA Pregnancy Category C. First trimester: Associated with cardiovascular malformations (e.g., Ebstein anomaly) in retrospective studies; risk approximately 1-2% absolute. Second and third trimesters: Limited data; theoretical risk of fetal tachyarrhythmia and neurobehavioral effects. Human data insufficient to exclude risk.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Amantadine is excreted into breast milk with an M/P ratio of approximately 0.5. Limited human data; potential for adverse effects in nursing infants (e.g., irritability, urinary retention). Caution advised; use only if potential benefit outweighs risk.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No specific pregnancy-related dosing adjustments established. Pharmacokinetic changes in pregnancy (increased renal clearance) may reduce serum levels; monitor clinical response and consider dose adjustment if efficacy wanes. Maximum dose 200 mg/day.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Amantadine is an antiviral and antiparkinsonian agent with NMDA receptor antagonist properties. For Parkinson's disease, it improves dyskinesias, especially levodopa-induced dyskinesias. For influenza A, it is less effective than neuraminidase inhibitors and resistance is common. Monitor for CNS effects (confusion, hallucinations, nightmares) especially in elderly or renally impaired patients. Dose adjustment required for Cr Cl <50 m L/min. Do not discontinue abruptly in Parkinson's disease due to risk of neuroleptic malignant syndrome.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,Avoid alcohol as it may increase dizziness or confusion.,Report any unusual thoughts, hallucinations, or severe confusion to your healthcare provider immediately.,If you have Parkinson's disease, this medicine helps control symptoms but does not cure it.,If you are taking for influenza, finish the full course even if you feel better.,May cause blurred vision or dizziness; avoid driving or operating machinery until you know how it affects you.,Stay hydrated but avoid excessive caffeine as it may exacerbate side effects.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
"Concurrent administration of naloxegol, a peripherally-acting mu-opioid receptor antagonist, may increase the serum concentration of amantadine, a weak NMDA receptor antagonist and antiviral agent. This interaction is proposed to occur via competitive inhibition of renal tubular secretion mediated by organic cation transporters (OCTs) present in the proximal tubule, leading to reduced amantadine clearance. Clinically, elevated amantadine levels can precipitate dose-related adverse effects including confusion, hallucinations, orthostatic hypotension, and peripheral edema, particularly in elderly patients or those with pre-existing renal impairment."
"Anagrelide is a phosphodiesterase 3 (PDE3) inhibitor with dose-dependent QT interval prolongation risk due to inhibition of the hERG potassium channel. Amantadine, a dopamine agonist and antiviral agent, also has mild QTc-prolonging properties, possibly through direct myocardial ion channel effects. Concomitant use may result in additive QT interval prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias."
"Amantadine, an antiviral and antiparkinsonian agent with weak NMDA receptor antagonist properties, may reduce the antipsychotic efficacy of mesoridazine, a phenothiazine antipsychotic. This interaction likely occurs via pharmacodynamic opposition, where amantadine's dopaminergic activity counteracts mesoridazine's dopamine receptor blockade in the central nervous system. Clinically, this can lead to worsening of psychotic symptoms or reduced therapeutic response to mesoridazine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMANTADINE vs ACEPHEN, answered by our medical review team.
AMANTADINE is a Antiviral / Antiparkinsonian that works by Amantadine is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of viral uncoating, thereby blocking influenza A M2 ion channel. In Parkinson's disease, it is thought to increase dopamine release and inhibit its reuptake, and may also have anticholinergic and NMDA receptor antagonist effects.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMANTADINE and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMANTADINE is: 100 mg orally twice daily for Parkinson's disease; 100 mg orally twice daily for influenza A prophylaxis/treatment (up to 200 mg/day).. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMANTADINE and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMANTADINE is classified as Category C. FDA Pregnancy Category C. First trimester: Associated with cardiovascular malformations (e.g., Ebstein anomaly) in retrospective studies; risk approximately 1-2% absolute. Second a. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.